Global Eczema Therapeutics Market is Segmented By Type of treatment (Corticosteroids, Emollients/moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics), By End-User ( Hospitals and Retail pharmacies, Drug stores, Online or mail pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Eczema Therapeutics Market Overview
The Global Eczema Therapeutics Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Eczema therapeutics include medications and treatments used for managing and treating eczema or atopic dermatitis. The market is driven by the increasing prevalence of eczema worldwide and the growing demand for effective therapeutic options. In the America region, the Global Eczema Therapeutics Market is witnessing significant growth. Key players in the market include Company A, Company B, Company C, and other prominent players operating in the market.
Eczema, also called atopic dermatitis, is a common skin condition marked by itchy and inflamed patches of skin. Topical corticosteroids, macrolide immunosuppressants, and oral immunomodulating drugs for recalcitrant disease have been the mainstay of therapy.
Eczema Therapeutics Market Scope
Market CAGR | High |
Segments Covered | By Type of treatment, By End-User, and By Region |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region | Asia Pacific |
Largest Market Share | North America |
For more insights - Download the Sample
Eczema Therapeutics Market Trends
The high prevalence of atopic dermatitis and the new product launches will drive the eczema therapeutics market in the forecast period.
The high prevalence of atopic dermatitis will drive the eczema therapeutics market
The most common type of eczema is atopic eczema (atopic dermatitis), the skin becomes dry, itchy and cracked. It is more common in children. AD may also develop for the first time in adults. The prevalence of AD is as high as 20% in children in some countries and continues to increase, affecting not only developed countries but also low-income countries.
Atopic dermatitis (AD) is a common skin inflammatory disease. Atopic eczema causes an itchy rash and dry skin and has a substantial impact on quality of life. Recent data suggests that in Europe and the USA, the prevalence of AD among children is around 20% and, among adults, it ranges between 7% and 14%, with substantial variation between countries. It leads to substantial social and financial costs and accounts for the largest global burden of disability owing to skin diseases. In approximately 80% of individuals the onset of AD occurs during the first years of life and about 60% experience remission in adolescence.
The new product launches will drive the eczema therapeutics market in the forecast period
Corticosteroid creams, foams, gels, ointments and solutions. The treatments, made with hydrocortisone steroids can reduce inflammation and quickly relieve itching. They come in different strengths, from stronger prescription medicines to mild over-the-counter (OTC) treatments.
To treat mild eczema the first thing doctors recommend is often OTC hydrocortisone. Patient may need different strengths of these steroids, depending on where and how bad the rash is. Doctor may prescribe a more potent one for thick, scaly skin.
PDE4 inhibitor is a prescription nonsteroidal anti-inflammatory called crisaborole (Eucrisa) can treat mild to moderate forms of eczema. A twice-a-day application for patients two and older has effectively easing inflammation and helping the skin look more like normal.
Dupixent® (dupilumab) was approved by U.S. FDA for children aged 6 to 11 years with moderate-to-severe atopic dermatitis which is not adequately controlled with topical prescription therapies or when those therapies are not advisable. For this patient population the only biologic medicine approved is dupixent . It comes in prefilled syringes and is available in two doses 200 mg and 300 mg. It was developed by Regeneron Pharmaceuticals and Sanofi Genzyme.
Side effects of the medication will hamper the eczema therapeutics market
Medicated creams topical steroids are put on the skin. They are used in addition to moisturizers (also called emollients) for treating eczema. Topical steroids reduce skin inflammation. Side effects from topical steroids can either be systemic or local. If it just affects a bit of skin then it is local and systemic means affecting the whole person. A stinging or burning feeling occurs when the treatment is applied. It is quite common but improves as the skin gets used to the treatment. Thinning of the skin has always been a common problem. Recent research suggests that this occurs mainly when high-strength steroids are used under airtight dressings. In regular normal use, skin thinning is unlikely and if it does occur, it often reverses when the topical steroid is stopped. With long-term use of topical steroids, the skin may develop permanent stretch marks (striae), discoloration, or thin spidery blood vessels (telangiectasias) and bruising. They may trigger or worsen other skin disorders such as acne, perioral dermatitis, and rosacea. Hair may grow on the area of skin being treated. Patients might develop an allergy to the contents or preservative used in the treatment. This may make the inflammation worse and irritate the skin being treated.
Topical steroid may sometimes get through the skin and into the bloodstream. The amount is small usually and causes no problems unless strong ones are used regularly on large areas of the skin. Children are the main concern, who need frequent courses of strong topical steroids. The steroid can affect growth. Therefore, regular growth monitoring should be done for children who need repeated courses of strong topical.
COVID-19 Impact on Eczema Therapeutics Market Growth
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and negative health from the COVID-19 pandemic. This has seen to affect the eczema therapeutics market as many pharmaceutical industries have stopped manufacturing units.
Eczema Therapeutics Market Segment and Shares
The corticosteroids segment will dominate the eczema therapeutics market
Corticosteroids are a drug class that lower inflammation in the body. They also reduce immune system activity. Topical corticosteroids are a type of steroid medicine applied to the skin directly to reduce irritation and inflammation. Most of the topical corticosteroids are considered safe to use during breastfeeding or pregnancy. Hydrocortisone which is a mild corticosteroids can often be bought over the counter from pharmacies. Stronger types are only available on prescription. Treatments made with hydrocortisone steroids can relieve itching quickly and reduce inflammation.
In the treatment of many dermatologic conditions topical corticosteroids play a major role. They are FDA-approved and indicated for dermatologic conditions. The well-known indications are for phimosis, acute radiation dermatitis psoriasis, limited areas of vitiligo, eczema, lichen simplex chronicus, discoid lupus erythematosus, atopic dermatitis, lichen planus, and lichen sclerosis. It is effective for conditions involving hyper-proliferation, immunological, and inflammatory properties.
Hospital and retail pharmacies and retail pharmacies will dominate the eczema therapeutics market
Worldwide atopic dermatitis affects 10–20% of children. Not all patients who receive treatment have optimal treatment outcomes. Consistent information from different health care providers about corticosteroids is essential, thus the key is optimal collaboration involved in the treatment of dermatitis between all health care providers. Pharmacist and technicians provide parents with practical (lifestyle) advice and assistance in choosing a emollient which is suitable for the optimal treatment of children with dermatitis. As patients generally fill their AD prescriptions in community pharmacies, pharmacists and technicians play an important role in patient counseling.
Wet dressings are an effective, intensive treatment for severe atopic dermatitis. It involves wrapping the affected area with topical corticosteroids and wet bandages. Sometimes this is done in a hospital for people with widespread lesions because it's labor-intensive and requires nursing expertise. Light therapy treatment is used for people who don't get better with topical treatments or rapidly flare again after treatment. The simplest form of light therapy (phototherapy) involves exposing the skin to controlled amounts of natural sunlight. Other forms use artificial ultraviolet A (UVA) and narrowband ultraviolet B (UVB) either alone or with medications. These treatments are done in a hospital in the presence of a doctor. Hence, the hospital and retail pharmacies segment will dominate the market.
Eczema Therapeutics Market Geographical Analysis
North America region will dominate the eczema therapeutics market
In the U.S. approximately 31.6 million people have some form of eczema. One in 10 individuals develop eczema during their lifetime, with prevalence peaking in early childhood. Around 9.6 million U.S. children under 18 have AD, and one-third have moderate to severe disease. The prevalence of childhood AD has increased steadily from 8% to ~12% since 1997. An estimated U.S. adults (7.3%) of 16.5 million have an atopic dermatitis that initially began at less than 2 years of age, with nearly 40 percent affected by moderate or severe disease. Atopic dermatitis is not solely a childhood onset disease. Onset of initial symptoms are reported by 1 in 4 adults. Atopic dermatitis affects a similar number of male and female children. However, studies have shown it is more common in adult females than males.
The U.S. FDA approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema. It is intended for use in patients whose eczema is not adequately controlled by topical therapies or for those whom topical therapies are not advisable. It can be used with or without topical corticosteroids. Regeneron and Sanofi are committed to help patients in the U.S. who have prescribed t0 gain access to theDupixen medicine and receive the support they may need with the DUPIXENT MyWay® program.
Eczema Therapeutics Companies and Competitive Landscape
Major key players in the eczema therapeutics market are Sanofi, Astellas Pharma, Anacor Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Meda AB, GlaxoSmithKline, AstraZeneca, Pfizer Inc., Hengrui Medicine, SYSVAX, and Hisun Pharmaceutical.
Global Eczema Therapeutics Market Key Companies to Watch
Sanofi
Overview: A global life sciences company sanofi is committed to improving access to healthcare and supporting the people they serve throughout the continuum of care. They transform scientific innovation into healthcare solutions in rare diseases human vaccines, human vaccines , immunology , oncology, multiple sclerosis, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare from prevention to treatment. At sanofi more than 110,000 people are dedicated to making a difference in patient's daily life.
Product Portfolio: The company engages in the manufacturing, research and development and marketing of pharmaceutical drugs primarily in the prescription market.The firm also develops over-the-counter medication. The company covers seven major therapeutic areas central nervous system, cardiovascular diabetes, internal medicine, oncology, thrombosis and vaccines.
Key Development: On august 6th 2019, Sanofi’s Dupixent® (dupilumab) was approved by European Commission for adolescents with moderate-to-severe atopic dermatitis.